STAT

‘It’s time for systemic change’: Scientific leaders urge new efforts to curb sexual harassment in the field

Leaders of one of the nation’s most prominent scientific groups are calling for the research community to "act with urgency" to address sexual and gender-based harassment in the field.
AAAS President Margaret Hamburg and other scientific leaders called for urgent action to address sexual harassment in science in a new editorial.

Leaders of one of the nation’s most prominent scientific groups are calling for the research community to “act with urgency” to address sexual and gender-based harassment in the field.

“It’s time for systemic change,” three leaders of the American Association for the Advancement of Science wrote in an editorial published Thursday in Science.

The editorial — penned by AAAS president Dr. Margaret Hamburg, chair of the board Susan Hockfield, and president-elect Steven Chu — follows on the heels of a new on harassment adopted by the organization last weekend. That policy allows the organization to revoke the membership of elected fellows in cases of proven scientific misconduct or serious breaches of professional ethics. The policy also makes it clear: Sexual and gender-based harassment violate those standards and are grounds for removal.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Brain Biopsies On ‘Vulnerable’ Patients At Mount Sinai Set Off Alarm Bells At FDA, Documents Show
A STAT Investigation: Brain biopsies on "vulnerable" patients at Mount Sinai set off alarm bells at FDA, documents show.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.

Related